Mapping the research landscape of nanotechnology based immunotherapy for hepatocellular carcinoma

绘制基于纳米技术的肝细胞癌免疫疗法的研究现状

阅读:2

Abstract

BACKGROUND: Advances in nanotechnology have introduced novel methodologies for immunotherapy targeting hepatocellular carcinoma (HCC). This study aims to develop a knowledge map and identify potential research hotspots in this field through bibliometric analysis. METHODS: Publications on HCC immunotherapy utilizing nanotechnology from 2005 to 2024 were obtained from the Web of Science Core Collection (WoSCC). Data visualization and statistical analysis were primarily conducted using VOSviewer, CiteSpace, R software, and Microsoft Office Excel 2021. RESULTS: The systematic search initially retrieved 600 publications from WoSCC, of which 10 were excluded during screening, yielding 590 publications on nanotechnology applications in HCC immunotherapy. Notably, the annual publication count surged from 44 papers in 2020 to 159 papers in 2024, representing an impressive 261% increase over this four-year period. China emerged as the foremost country in publishing volume and international collaborations, although its articles receive relatively few average citations. The USA, ranking second in output, achieves the highest average citation count. The timeline visualization of reference reveals three distinct phases (2005–2009, 2010–2018, and 2019–2024) with the following seven reference clusters: #0 cancer chitosan nanoparticle, #1 hepatocellular carcinoma, #2 antigen presentation, #3 carbon nanotube, #4 targeting PD-L1 expression, #5 natural killer cell, and #6 liver metastases. “Cancer microenvironment”, “drug delivery”, “immunogenic cell death”, and “combination therapy” showed extremely high occurrence frequencies. “mRNA”, “mRNA delivery”, “metabolism” were the key keywords that have emerged recently. CONCLUSION: Nanotechnology-based immunotherapy field has evolved from foundational nanoparticle development (2005–2009) to immune microenvironment modulation (2010–2018) and now embraces mRNA-based precision immunotherapy (2019–2024). Future efforts may prioritize combinatorial nano-immunotherapies integrating metabolic regulation and AI-optimized delivery.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。